.svg){kind=small}
Oct-2025
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
Canna Clinicals has maintained a consistent presence in the New York market, particularly within the Tincture & Sublingual category. Over the months from July to October 2025, the brand has consistently held its position around the eighth and ninth ranks, demonstrating a stable performance. This consistency indicates a strong foothold in the market, as they have managed to stay within the top 10 brands in this category. Notably, there was a slight dip in August, but the brand quickly rebounded to its previous rank by September. This resilience suggests effective brand strategies and consumer loyalty in the state.
While Canna Clinicals has shown stability in New York, their absence in the top 30 rankings across other states and categories could be seen as a potential area for growth or concern. The absence of rankings in other states suggests that the brand might be focusing its efforts primarily within New York, or it may indicate a need for expansion and increased market penetration elsewhere. This limited presence outside of New York could be a strategic decision or a reflection of competitive challenges in other markets. Observing how Canna Clinicals addresses this in the coming months will be crucial for understanding their broader market strategy.
Competitive Landscape
In the competitive landscape of the Tincture & Sublingual category in New York, Canna Clinicals has maintained a consistent presence, ranking 8th in July, September, and October 2025, with a slight dip to 9th in August. This stability in ranking is noteworthy, especially when compared to competitors like High Falls Canna New York, which improved its position from 7th to 6th by October, and OMO - Open Minded Organics, which consistently held a top 5 position. Despite facing a challenging market, Canna Clinicals' sales showed resilience, particularly in October, where sales rebounded to levels similar to July. Meanwhile, Ithaca Organics Cannabis Co. entered the top 10 in September and maintained its 9th position in October, indicating a rising competitive pressure. The data suggests that while Canna Clinicals has managed to hold its ground, there is a need for strategic initiatives to climb higher in rankings and capitalize on sales opportunities.
Notable Products
In October 2025, the top-performing product from Canna Clinicals was the CBD/THC 1:10 Max Strength Tincture (100mg CBD, 1000mg THC, 30ml), maintaining its first-place ranking with notable sales of 503 units. The CBD/THC Unwind Tincture (1050mg CBD, 90mg THC, 15ml) also held steady in second place. The CBD/THC Balance Tincture (100mg CBD, 500mg THC) rose from fifth to third place, indicating a growing consumer interest. Meanwhile, the CBD/THC 1:1 Max Strength Capsules 10-Pack (100mg CBD, 100mg THC) slipped from third to fourth place. The CBD/CBN/THC Sleep Tincture (300mg CBD, 300mg CBN, 150mg THC) moved down to fifth place, showing a slight decrease in demand compared to the previous month.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
